Labeling is based on the agency's thorough analysis of the new drug application (NDA) or biological license application. The labeling, or prescribing information, is thus subject to FDA ...
Anticipation of a Biological License Application (BLA) submission in 2026, contingent on ELPIS II success, represents a significant potential milestone for the company. Total revenue for 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback